Artelo Biosciences Q2 FY26 net loss narrows 24.65% to USD 2.43 million

• Artelo Biosciences posted a net loss of USD 2.43 million, narrowing from USD 3.22 million a year earlier.
• Operating loss narrowed to USD 2.51 million as operating expenses fell to USD 2.51 million from USD 3.15 million.
• Research and development expense dropped to USD 876,000 from USD 1.87 million, mainly on lower CAReS trial spending.
• General and administrative costs rose to USD 1.63 million from USD 1.28 million.
• Cash, cash equivalents and investments totaled USD 4.2 million at June 30, 2026; the company entered a USD 6.53 million at-the-market program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001640334-26-001323), on August 12, 2026, and is solely responsible for the information contained therein.